California State Teachers Retirement System (CalSTRS)’s Candel Therapeutics CADL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.6K Sell
2,372
-327
-12% -$1.78K ﹤0.01% 2628
2025
Q4
$15.2K Buy
2,699
+243
+10% +$1.31K ﹤0.01% 2625
2025
Q3
$12.5K Buy
2,456
+2
+0.1% +$12 ﹤0.01% 2753
2025
Q2
$12.4K Buy
2,454
+839
+52% +$4.32K ﹤0.01% 2660
2025
Q1
$9.13K Hold
1,615
﹤0.01% 2783
2024
Q4
$14K Buy
1,615
+179
+12% +$1.06K ﹤0.01% 2741
2024
Q3
$9.95K Hold
1,436
﹤0.01% 2877
2024
Q2
$8.9K Buy
+1,436
New +$10.8K ﹤0.01% 2935

Other funds holding CADL

California State Teachers Retirement System (CalSTRS)'s CADL Position: Q1 2026 in Review

California State Teachers Retirement System (CalSTRS) reduced its Candel Therapeutics (CADL) stake by 12% in Q1 2026, selling an estimated $1.78K and leaving 2,372 shares worth $11.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2628.

California State Teachers Retirement System (CalSTRS) first reported a position in CADL in Q2 2024 and has held it in 8 quarters since. The position peaked at $15.2K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • California State Teachers Retirement System (CalSTRS) held 2,372 shares of Candel Therapeutics worth $11.6K as of Q1 2026.
  • California State Teachers Retirement System (CalSTRS) sold 327 Candel Therapeutics shares in Q1 2026, an estimated $1.78K.
  • Candel Therapeutics made up ﹤0.01% of California State Teachers Retirement System (CalSTRS)'s portfolio in Q1 2026, its #2628 holding.
  • California State Teachers Retirement System (CalSTRS) first reported a position in Candel Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • California State Teachers Retirement System (CalSTRS)'s Candel Therapeutics position peaked at $15.2K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on California State Teachers Retirement System (CalSTRS)'s 13F filing for Q1 2026, filed 18 May 2026.